Hims & Hers Health, Inc. (HIMS)
EARNINGS ALERT: HIMS
While Palantir (PLTR) trading was vastly unchanged after hours , Hims & Hers (HIMS) saw some downside action following its earnings. George Tsilis notes it has "become quite profitable over the years," attributing part of the sell-off to the telehealth company's valuation.
Can Sustained Product Demand Drive HIMS Stock Before Q1 Earnings?
The continued solid uptake of Hims & Hers offerings and expanding subscriber base are likely to have driven the company's performance in the first quarter of 2025.
Hims & Hers: Revolutionizing Healthcare
The company's vertically integrated platform enhances scalability and efficiency, controlling the entire patient experience from consultation to medication delivery. Partnerships, especially with Novo Nordisk for GLP-1 weight-loss drugs, significantly boost revenue and deepen customer relationships. Embracing AI and peptide therapies positions Hims & Hers for future growth, though regulatory compliance and reliance on third-party suppliers pose risks.
Buy Hims (HIMS) or Novo Nordisk (NVO) Stock After Partnership Announcement?
Medical pioneers Hims & Hers Health (HIMS) and Novo Nordisk (NVO) are making headlines this week after announcing a partnership to expand obesity care in the telehealth space.
Hims & Hers vs. Teladoc: Which Telehealth Stock Is the Better Buy Now?
Both HIMS and TDOC are technology-intensive healthcare companies that leverage their strengths in the digital health space to enhance their platforms. Which one is a better investment?
Hims & Hers Stock Soars on Novo Nordisk Collaboration
Every once in a while, investors come across some of the best names in a given industry, which then become subject to the best news and developments during a holding period. Today's best pick seems to be in the medical sector.
Hims & Hers stock price soars after partnership with Novo Nordisk to offer weight-loss drug Wegovy
Shares in Hims & Hers Health, Inc. (NYSE: HIMS) are skyrocketing in early-morning trading today after the telehealth company announced a new partnership with the Danish pharmaceutical giant Novo Nordisk. That partnership will see Hims & Hers offer Novo Nordisk's weight-loss drug Wegovy through its platform.
Hims & Hers Health (HIMS) Stock Jumps 23.0%: Will It Continue to Soar?
Hims & Hers Health (HIMS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Hims & Hers stock pops on Novo Nordisk partnership
Hims & Hers (NYSE:HIMS) shares surged after it announced a partnership with Novo Nordisk that will allow it to offer the drugmaker's weight loss product Wegovy through its telehealth platform. Investors welcomed the collaboration, which positions Hims & Hers to participate directly in the fast-growing market for GLP-1 weight-loss drugs.
Hims & Hers partners with Novo Nordisk to sell Wegovy
Hims & Hers on Tuesday announced a collaboration with drugmaker Novo Nordisk to bundle Wegovy and a Hims & Hers membership on its telehealth platform.
Hims & Hers Stock Rides Wegovy Wave Higher
Hims & Hers Health Inc (NYSE:HIMS) stock is soaring today, up 22.6% at $34.92 at last glance, after news that the telehealth platform will offer Novo Nordisk's (NVO) popular weight-loss drug, Wegovy.
Wegovy Today, Ozempic Tomorrow: Partnership With Novo Is Hims & Hers Comeback
Hims & Hers Health, Inc. just announced a partnership with Novo Nordisk, Ro and LifeMD to sell their Wegovy at a discounted price. The deal is a game changer, enabling Hims to offer Wegovy at $599/month versus $1,999/month. I think this deal hints at potential to do the same with Ozempic further boosting the stock, which is already up +30% in pre-market trading.
